Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vabicaserin Safety and Efficacy in Japanese Subjects with Acute Schizophrenia
NCT00768612Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Nov 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of vabicaserin in schizophrenia, sponsored by Pfizer. Planned start Nov 2008; status: withdrawn.
02
Drugs
vabicaserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00768612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768612.